(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060896 A1

(51) International Patent Classification[7]: C07D 405/12, A61K 31/44, A61P 11/06, 29/00

(21) International Application Number: PCT/IB01/02726

(22) International Filing Date:
24 December 2001 (24.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/265,304 31 January 2001 (31.01.2001) US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CHAMBERS, Robert, James** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **MAGEE, Thomas, Victor** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **MARFAT, Anthony** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

WO 02/060896 A1

(54) Title: ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES

(57) Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula (I) wherein j is 0 or 1, provided that when j is 0, n must be 2; k is 0 or 1; m is 1, 2, or 3; n is 1 or 2; W^1 and W^2 are -O-; $-S(=O)_t-$, where t is 0, 1, or 2, or $-N(R^3)-$; Y is $=C(R^1{}_a)-$, or $-[N\Rightarrow(O)_k]-$ where k is 0 or 1; $R^1{}_a$ is -H, -F, -Cl, -CN, $-NO_2$, $-(C_1-C_4)$ alkyl, $-(C_2-C_4)$ alkynyl, fluorinated-(C_1-C_3) alkyl, fluorinated-(C_1-C_3) alkoxy, $-OR^{16}$, or $-C(=O)NR^{22}{}_aR^{22}{}_b$; R^A and R^B are -H, -F, $-CF_3$, $-(C_1-C_4)$ alkyl, $-(C_3-C_7)$ cycloalkyl, phenyl, or benzyl substituted by 0-3 R^{10}; or R^A and R^B are taken together to form a spiro moiety of the formula (Ia) where r and s are 0-4 provided r + s is ≥1 but not > 5; and X^A is $-CH_2-$, -CHF, $-CF_2$, $-NR^{15}-$, -O-, or $-S(=O)_t-$, where t is 0, 1; R^C and R^D are the same as R^A and R^B except that one of them must be -H; R^1 and R^2 are -H, -F, -Cl, -CN, $-NO_2$, $-(C_1-C_4)$ alkyl, $-(C_2-C_4)$ alkynyl, fluorinated-(C_1-C_3) alkyl, $-OR^{16}$, or $-C(=O)NR^{22}{}_aR^{22}{}_b$; R^3 is -H, $-(C_1-C_3)$ alkyl, phenyl, benzyl, or $-OR^{16}$; R^4, R^5 and R^6, D, J_1 and J_2 are defined in the application.